MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by U’PRICHARD, D. C.
Right arrow Articles by SNYDER, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by U’PRICHARD, D. C.
Right arrow Articles by SNYDER, S. H.

Molecular Pharmacology, Vol 13, 454-473, Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics

Binding Characteristics of a Radiolabeled Agonist and Antagonist at Central Nervous System Alpha Noradrenergic Receptors

DAVID C. U’PRICHARD 1, DAVID A. GREENBERG 1, and SOLOMON H. SNYDER 1

1 Departments of Pharmacology and Experimental Therapeutics and of Psychiatry and the Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Binding of the alpha noradrenergic agonist [3H]clonidine and the alpha antagonist [3H]WB-4101 (2-([2',6'-dimethoxy]phenoxyethylamino)methylbenzodioxan) to rat brain membranes exhibits characteristics expected of alpha receptors for norepinephrine. Binding of both [3H]ligands is saturable, with KD values of 5.8 nM and 0.48 nM for [3H]clonidine and [3H]WB-4101, respectively. A series of catecholamines inhibits the binding of both ligands with the potency order epinephrine > norepinephrine >> isoproterenol, corresponding to the relative activities of these agents at alpha receptors in the periphery. Competition for binding is stereoselective, with (-) isomers of phenylethanolamines many times more potent than the corresponding (+) isomers. Classical alpha antagonists inhibit binding of both ligands at low concentrations, but beta antagonists are much weaker. Alpha agonists are more potent in displacing [3H]clonidine than [3H]WB-4101 binding, while alpha antagonists compete more avidly for [3H]WB-4101 sites. Partial agonist ergot alkaloids display similar affinities for the binding sites of both [3H]ligands. These findings may be explained by the existence of discrete agonist and antagonist states of the alpha receptor, which preferentially bind [3H]clonidine and [3H]WB-4101, respectively. Regional variations in the binding of both [3H]ligands in the brain are not pronounced, although levels tend to be highest in hypothalamus and cerebral cortex and lowest in cerebellum. Treatment with 6-hydroxydopamine fails to decrease the binding of either [3H]ligand, suggesting that binding occurs to postsynaptic sites.

Note:
ACKNOWLEDGMENT We thank Mr. Stephen J. Peroutka for his skillful technical assistance.

Submitted on August 16, 1976
Accepted on December 9, 1976




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
T. Johansson, P.-A. Frandberg, F. Nyberg, and P. Le Greves
Molecular Mechanisms for Nanomolar Concentrations of Neurosteroids at NR1/NR2B Receptors
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 759 - 768.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
L. E. Limbird
The Receptor Concept: A Continuing Evolution
Mol. Interv., December 1, 2004; 4(6): 326 - 336.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
P. Ferrari, L. Torielli, M. Ferrandi, G. Padoani, L. Duzzi, M. Florio, F. Conti, P. Melloni, L. Vesci, N. Corsico, et al.
PST2238: A New Antihypertensive Compound That Antagonizes the Long-Term Pressor Effect of Ouabain
J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 83 - 94.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
J. W. Hubbard, S. T. Nordstrom, C. P. Smith, K. M. Brooks, L. Laws-Ricker, L. Zhou, and H. M. Vargas
alpha -Adrenergic Activity and Cardiovascular Effects of Besipirdine HCl (HP 749) and Metabolite P7480 in Vitro and in the Conscious Rat and Dog
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 337 - 346.
[Abstract] [Full Text]


Home page
ScienceHome page
J. Wagner, I. Reynolds, H. Weisman, P Dudeck, M. Weisfeldt, and S. Snyder
Calcium antagonist receptors in cardiomyopathic hamster: selective increases in heart, muscle, brain
Science, April 25, 1986; 232(4749): 515 - 518.
[Abstract] [PDF]


Home page
ScienceHome page
S. Snyder
Drug and neurotransmitter receptors in the brain
Science, April 6, 1984; 224(4644): 22 - 31.
[Abstract] [PDF]


Home page
ScienceHome page
S. Peroutka, M. Moskowitz, J. Reinhard Jr, and S. Snyder
Neurotransmitter receptor binding in bovine cerebral microvessels
Science, May 9, 1980; 208(4444): 610 - 612.
[Abstract] [PDF]


Home page
ScienceHome page
A Maggi, D. U'Prichard, and S. Enna
beta-Adrenergic regulation of alpha 2-adrenergic receptors in the central nervous system
Science, February 8, 1980; 207(4431): 645 - 647.
[Abstract] [PDF]


Home page
ScienceHome page
K. Minneman, M. Dibner, B. Wolfe, and P. Molinoff
beta1- and beta2-Adrenergic receptors in rat cerebral cortex are independently regulated
Science, May 25, 1979; 204(4395): 866 - 868.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1977 by the American Society for Pharmacology and Experimental Therapeutics